These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504 [TBL] [Abstract][Full Text] [Related]
3. Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I. Horrevorts SK; Duinkerken S; Bloem K; Secades P; Kalay H; Musters RJ; van Vliet SJ; García-Vallejo JJ; van Kooyk Y Front Immunol; 2018; 9():1231. PubMed ID: 29963041 [TBL] [Abstract][Full Text] [Related]
4. Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells. Garcia-Vallejo JJ; Koning N; Ambrosini M; Kalay H; Vuist I; Sarrami-Forooshani R; Geijtenbeek TB; van Kooyk Y Int Immunol; 2013 Apr; 25(4):221-33. PubMed ID: 23291968 [TBL] [Abstract][Full Text] [Related]
5. Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1. Sabado RL; Babcock E; Kavanagh DG; Tjomsland V; Walker BD; Lifson JD; Bhardwaj N; Larsson M Eur J Immunol; 2007 Jul; 37(7):1752-63. PubMed ID: 17534864 [TBL] [Abstract][Full Text] [Related]
6. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Tacken PJ; de Vries IJ; Gijzen K; Joosten B; Wu D; Rother RP; Faas SJ; Punt CJ; Torensma R; Adema GJ; Figdor CG Blood; 2005 Aug; 106(4):1278-85. PubMed ID: 15878980 [TBL] [Abstract][Full Text] [Related]
7. Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and ICAM molecules favors the receptor's role as an antigen-capturing rather than an adhesion receptor. Snyder GA; Ford J; Torabi-Parizi P; Arthos JA; Schuck P; Colonna M; Sun PD J Virol; 2005 Apr; 79(8):4589-98. PubMed ID: 15795245 [TBL] [Abstract][Full Text] [Related]
8. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Tacken PJ; Ginter W; Berod L; Cruz LJ; Joosten B; Sparwasser T; Figdor CG; Cambi A Blood; 2011 Oct; 118(15):4111-9. PubMed ID: 21860028 [TBL] [Abstract][Full Text] [Related]
9. Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine. García-Piñeres AJ; Hildesheim A; Trivett M; Williams M; Wu L; Kewalramani VN; Pinto LA Eur J Immunol; 2006 Feb; 36(2):437-45. PubMed ID: 16385626 [TBL] [Abstract][Full Text] [Related]
10. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175 [TBL] [Abstract][Full Text] [Related]
11. Sugar and spice: viral envelope-DC-SIGN interactions in HIV pathogenesis. Su SV; Gurney KB; Lee B Curr HIV Res; 2003 Jan; 1(1):87-99. PubMed ID: 15043214 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. van Montfort T; Eggink D; Boot M; Tuen M; Hioe CE; Berkhout B; Sanders RW J Immunol; 2011 Nov; 187(9):4676-85. PubMed ID: 21957147 [TBL] [Abstract][Full Text] [Related]
19. A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Schjetne KW; Thompson KM; Aarvak T; Fleckenstein B; Sollid LM; Bogen B Int Immunol; 2002 Dec; 14(12):1423-30. PubMed ID: 12456590 [TBL] [Abstract][Full Text] [Related]
20. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. Engering A; Geijtenbeek TB; van Vliet SJ; Wijers M; van Liempt E; Demaurex N; Lanzavecchia A; Fransen J; Figdor CG; Piguet V; van Kooyk Y J Immunol; 2002 Mar; 168(5):2118-26. PubMed ID: 11859097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]